ESPR Esperion Therapeutics, Inc. Earnings per share for the last twelve months

ESPR (Esperion Corp) - company brandmark

Annual net income per share demonstrates the resilience of Esperion Therapeutics (ESPR), despite geopolitical risks and challenges with international patenting. The company is capturing the non-statin cholesterol-fighting niche, creating an affordable alternative to injections. However, pressure from insurers limits pricing power, and -0.10 represents the current metric value.

ESPR (Esperion Therapeutics) Net earnings per share for the last four quarters history from 07/04/2022 to 07/25/2026

Financial and market metric breakdowns for Esperion Therapeutics (ESPR)

- stock price and consensus target price:
General company analysis:Esperion Therapeutics - ESPR
Mass-produced product of Esperion Corp

This indicator calculates the net income distributed per common share over a rolling year, allowing for an assessment of real capital efficiency without issuance distortions. By analyzing the rolling 12-month earnings per share, an investor can see how licensing fees from Nexletol partnerships and the M&A activity of Esperion Therapeutics (ESPR) translate into concrete financial returns for every shareholder.